Case Vignettes in Metastatic Breast Cancer
This case-based program is designed to educate healthcare providers on the optimal management of patients with ER+/HER2– MBC, with the goal of improving patient outcomes including quality of life and survival.
Activity Overview
This activity is designed to educate medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, and other allied health professionals on the optimal management of metastatic breast cancer.
This case-based program is designed to educate these healthcare providers on the optimal management of patients with ER+/HER2 MBC, with the goal of improving patient outcomes including quality of life and survival.
To view this CME activity, click here >>>
Educational Objectives
Upon completing this activity as designed, participants should be able to:
- Review clinical trial data on current and emerging treatments for patients with ER-positive/HER2-negative MBC
- Evaluate efficacy and safety data on currently available chemotherapeutic agents for patients with ER-positive/HER2-negative MBC
- Describe optimal management strategies recommended by evidence-based guidelines for the treatment of patients with ER-positive/HER2- negative MBC
- Develop individualized treatment plans with consideration for key patient and clinical factors for patients with ER-positive/HER2-negative MBC
Target Audience:Medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, and other allied health professionals.
Type of Activity:Knowledge
Release date:April 30, 2015
Expiration date:April 30, 2016
Estimated time to complete activity:2 hours
To view this CME activity, click here >>>
Featuring Consultations With
Joyce O'Shaughnessy, MD
Chair, Breast Cancer Research
Baylor-Sammons Cancer Center
Texas Oncology, US Oncology
Dallas, TX
Linda T. Vahdat, MD
Professor of Medicine
Director of the Breast Cancer Research Program,
Chief of the Solid Tumor Service
Weill Cornell Medical College
New York, NY
With Community Oncologist's Perspective by
Hussein Ali-Ahmad, MD
Clinical Assistant Professor of Oncology
Roswell Park Cancer Institute
Jamestown, NY
Editorial Support
Sigrid Eckhardt
Hitt Medical Writing, LLC
This activity is supported by an educational grant from Eisai.
Improving the Transition From Inpatient to Outpatient Care in Oncology
November 27th 2024A recent Targeted Oncology survey explores the challenges and best practices in transitioning patients with cancer from inpatient to outpatient care, featuring insights from Cristina Gasparetto, MD, on improving these processes.
Read More
Phase 1b/2 Study of BXQ-350 in Metastatic Colorectal Cancer Completes Enrollment
November 27th 2024Enrollment has been completed for the phase 1b/2 ASIST study that is evaluating BXQ-350 in combination with standard-of-care treatments in patients with newly diagnosed metastatic colorectal cancer.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
